deltatrials
Terminated PHASE1 NCT01078974

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia

Sponsor: Celgene Corporation

Conditions Waldenstrom's Macroglobulinemia
Interventions dexamethasone pomalidomide rituximab
Updated 7 times since 2017 Last updated: Jun 13, 2016 Started: May 31, 2010 Primary completion: Sep 30, 2015 Completion: Mar 31, 2016

This PHASE1 trial investigates Waldenstrom's Macroglobulinemia and is currently terminated or withdrawn. Celgene Corporation leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • Steven P. Treon, MD, PhD
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States